Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping

Between 20% and 50% of cardiovascular patients treated with clopidogrel, an anti‐P2Y12 drug, display high on‐treatment platelet reactivity (HTPR) and are not adequately protected from major adverse cardiovascular events (MACE). Despite a minor influence of the CYP2C19*2 genetic variant on the pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontana, Pierre, Cattaneo, Marco, Combescure, Christophe, Reny, Jean‐Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Special Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647256/
https://www.ncbi.nlm.nih.gov/pubmed/23537811
http://dx.doi.org/10.1161/JAHA.112.000131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647256/
https://www.ncbi.nlm.nih.gov/pubmed/23537811
http://dx.doi.org/10.1161/JAHA.112.000131

Ejemplares similares